Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001049922 | SCV001214000 | uncertain significance | Glycogen storage disease type III | 2021-08-24 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with threonine at codon 846 of the AGL protein (p.Ile846Thr). The isoleucine residue is moderately conserved and there is a moderate physicochemical difference between isoleucine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with AGL-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001049922 | SCV002091551 | uncertain significance | Glycogen storage disease type III | 2021-05-28 | no assertion criteria provided | clinical testing |